Polyvagal Theory: Vagal Tone, Neuroception, Clinical Applications, and the Current Evidence Base

Polyvagal Theory (PVT), introduced by Stephen Porges in 1995 and elaborated in his landmark 1995 Psychophysiology paper and subsequent 2011 monograph The Polyvagal Theory: Neurophysiological Foundations of Emotions, Attachment, Communication, and Self-Regulation, represents one of the most influential — and most contested — frameworks linking autonomic nervous system (ANS) function to psychological states, social behavior, and trauma responses. PVT proposes that the mammalian autonomic nervous system evolved a hierarchical organization with three phylogenetically distinct circuits, each mediating distinct behavioral strategies: social engagement, mobilization (fight-or-flight), and immobilization (shutdown/collapse).

The theory has gained enormous traction in clinical psychology, particularly in trauma-focused therapies, somatic experiencing, attachment-based interventions, and body-oriented psychotherapies. Therapists across disciplines now routinely reference "ventral vagal states," "dorsal vagal shutdown," and "neuroception" in clinical formulation. However, PVT has also attracted substantial criticism from neuroanatomists and physiologists who argue that several of its core phylogenetic and neuroanatomical claims are either oversimplified or inconsistent with comparative neuroscience evidence.

This article provides an in-depth examination of PVT's neurobiological foundations, the construct of neuroception, the psychophysiology of vagal tone as measured by heart rate variability (HRV), clinical applications across diagnostic categories, and a rigorous appraisal of the current evidence base — including both supportive findings and significant criticisms.

The central neuroanatomical claim of PVT is that the vagus nerve — cranial nerve X — is not a unitary structure but comprises two functionally and phylogenetically distinct branches with different brainstem origins:

• The dorsal vagal complex (DVC): Originating in the dorsal motor nucleus of the vagus (DMNX), this unmyelinated vagal pathway is described as phylogenetically older, shared with reptiles, and mediating immobilization responses including bradycardia, apnea, syncope, and behavioral shutdown. In PVT, extreme activation of this system produces the "freeze" or "collapse" responses seen in dissociation and tonic immobility.
• The ventral vagal complex (VVC): Originating in the nucleus ambiguus (NA), this myelinated vagal pathway is described as uniquely mammalian and linked to the social engagement system. It provides rapid, tonic regulation of heart rate through the cardiac vagal brake, and is anatomically and functionally integrated with the cranial nerves that control facial expression (CN VII), vocalization (CN IX, X), head turning (CN XI), and middle ear muscles — collectively enabling social communication.
• The sympathetic nervous system: Mediating classical fight-or-flight mobilization via the sympathetic chain and adrenal medulla, positioned phylogenetically between the dorsal and ventral vagal systems.

Porges proposes a phylogenetic hierarchy in which these systems are recruited in reverse evolutionary order under threat — a principle he terms dissolution (borrowing from Hughlings Jackson). Under safety, the ventral vagal system dominates, supporting calm social engagement. When safety cues are insufficient, the sympathetic system is recruited for active defense. When sympathetic defense fails or is impossible, the dorsal vagal system produces immobilization, which in extreme forms manifests as dissociative shutdown.

The Social Engagement System

A distinctive contribution of PVT is the concept of the social engagement system (SES), a functional network integrating myelinated vagal control of the heart with somatomotor control of striated muscles in the face and head. Porges argues that in mammals, the neural regulation of the viscera (via NA vagal pathways) became integrated with the branchiomotor nuclei controlling the muscles of facial expression, mastication, vocalization, and listening. This integration means that autonomic state and social behavior are bidirectionally coupled: calming the autonomic nervous system facilitates social engagement, and social engagement (e.g., prosodic voice, warm facial expressions) calms the autonomic nervous system.

Neuroanatomically, the SES involves convergent projections in the brainstem reticular formation, with the NA receiving input from cortical and subcortical structures including the central nucleus of the amygdala, the hypothalamus, and prefrontal regions — particularly the medial prefrontal cortex (mPFC) and insula, which are critically involved in interoception and emotional regulation.

Neuroception is Porges's term for the neural process by which the nervous system evaluates risk in the environment without requiring conscious awareness. Unlike perception (a conscious process) or appraisal (a cognitive process), neuroception is described as a subcortical, automatic evaluation that triggers shifts in autonomic state. Neuroception determines whether the nervous system deploys the social engagement system, sympathetic mobilization, or dorsal vagal shutdown.

Neural Substrates of Neuroception

While Porges does not specify a single neural circuit for neuroception, the construct maps onto several well-characterized subcortical threat-detection systems:

• Amygdala (particularly the basolateral and central nuclei): Rapid, preconscious evaluation of threat stimuli, with direct projections to the DMNX, NA, and sympathetic preganglionic neurons. The amygdala's capacity for subliminal threat detection — demonstrated in studies using backward-masked fearful faces showing amygdala activation below conscious awareness (Whalen et al., 1998) — provides a plausible neural substrate for neuroception.
• Superior temporal sulcus (STS) and fusiform face area: Critical for processing biological motion, facial expressions, and vocal prosody — the social cues that PVT identifies as triggers for neuroception of safety.
• Insula: The anterior insula integrates interoceptive signals with environmental context, providing a cortical substrate for the awareness of autonomic state shifts. Craig's model of interoceptive awareness parallels PVT's emphasis on body-state awareness.
• Periaqueductal gray (PAG): The PAG organizes defensive behaviors (freezing, flight, fight) and has direct connections to vagal motor nuclei. Activation of the ventrolateral PAG column produces bradycardia, hypotension, and behavioral quiescence — consistent with PVT's dorsal vagal immobilization response.
• Prefrontal cortex: The mPFC exerts top-down regulation over amygdala-driven autonomic responses, modulating the threshold for neuroception of threat. Impaired mPFC function — as documented in PTSD neuroimaging studies (Shin et al., 2005) — may lower the threshold for threat neuroception, producing hypervigilance and exaggerated autonomic reactivity.

Faulty Neuroception as a Transdiagnostic Mechanism

Porges proposes that faulty neuroception — misidentifying safety as threat, or threat as safety — underlies multiple psychiatric conditions. In PTSD, faulty neuroception manifests as chronic threat detection in objectively safe environments. In autism spectrum disorder (ASD), faulty neuroception may contribute to social avoidance despite non-threatening social contexts. In borderline personality disorder (BPD), neuroceptive instability may drive rapid oscillations between approach and defensive states. This transdiagnostic framing has made the concept clinically attractive, though its specificity as a mechanism remains empirically underdeveloped.

Vagal tone — the tonic inhibitory influence of the myelinated vagus on the sinoatrial node of the heart — is the primary quantifiable biomarker associated with PVT. Vagal tone is indexed by respiratory sinus arrhythmia (RSA), also called high-frequency heart rate variability (HF-HRV), which reflects the rhythmic acceleration and deceleration of heart rate synchronized with respiration. RSA is mediated by the myelinated vagal fibers originating in the NA and is a validated, non-invasive measure of parasympathetic cardiac control.

Measurement Approaches

HRV is typically derived from electrocardiogram (ECG) or photoplethysmography (PPG) recordings and analyzed in two primary domains:

• Time-domain measures: RMSSD (root mean square of successive differences in interbeat intervals) is the most commonly used time-domain index of vagal tone. RMSSD values in healthy adults typically range from 20-80 ms, with higher values indicating greater vagal tone.
• Frequency-domain measures: The high-frequency (HF) band (0.15-0.40 Hz) of the HRV power spectrum reflects RSA and parasympathetic activity. The low-frequency (LF) band (0.04-0.15 Hz) reflects a mix of sympathetic and parasympathetic influences; the LF/HF ratio, once thought to index sympathovagal balance, is now considered unreliable for this purpose.

Vagal Tone as a Biomarker: Empirical Findings

A substantial literature links reduced vagal tone (low HF-HRV/RSA) to psychopathology across multiple diagnostic categories:

• PTSD: A meta-analysis by Nagpal et al. (2013) found significantly reduced resting HF-HRV in PTSD relative to controls, with a pooled effect size of approximately d = −0.41 to −0.60 across studies. The PTSD-HRV relationship is moderated by trauma type, comorbid depression, and medication status.
• Depression: Kemp et al. (2010) conducted a meta-analysis reporting reduced HRV in major depressive disorder (MDD), with effect sizes of d = −0.33 for HF-HRV relative to healthy controls, persisting after adjustment for medication effects. Importantly, antidepressant medications — particularly tricyclics and SNRIs — independently reduce HRV via anticholinergic mechanisms.
• Anxiety disorders: Chalmers et al. (2014) found reduced HF-HRV across anxiety disorders including generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder (pooled d ≈ −0.29 to −0.45), with the largest effects in GAD.
• Schizophrenia: Clamor et al. (2016) reported reduced vagal tone in schizophrenia spectrum disorders, with meta-analytic effect sizes around d = −0.50.
• Autism spectrum disorder: Several studies show atypical RSA in ASD, though findings are mixed regarding direction and magnitude. Porges and colleagues have found reduced RSA baseline and atypical RSA reactivity to social stimuli in children with ASD.

The Neurovisceral Integration Model

Thayer and Lane's neurovisceral integration model provides a complementary framework linking HRV to prefrontal-subcortical regulation of emotion. In this model, HRV indexes the functional integrity of the central autonomic network — including the mPFC, anterior cingulate cortex (ACC), insula, amygdala, and brainstem nuclei — in regulating peripheral autonomic function. Neuroimaging studies confirm that resting HF-HRV correlates positively with mPFC activation during emotion regulation tasks and negatively with amygdala reactivity to threat stimuli. This model converges with PVT's emphasis on ventral vagal regulation but grounds it in well-characterized cortico-subcortical circuits.

PVT has profoundly influenced clinical practice, particularly in trauma-focused and body-oriented psychotherapies. The theory's hierarchical model of autonomic states provides clinicians with a language for understanding and addressing the somatic dimensions of psychological distress.

Trauma-Focused Applications

In PTSD treatment, PVT-informed approaches emphasize the restoration of ventral vagal function and the capacity for neuroception of safety. Key clinical applications include:

• Sensorimotor Psychotherapy (Pat Ogden): Explicitly integrates PVT in addressing "window of tolerance" — the zone of ventral vagal regulation within which emotional processing is possible. Interventions target the expansion of this window by gradually building the client's capacity to tolerate autonomic arousal without dissociation (dorsal vagal collapse) or hyperarousal (sympathetic dominance).
• Somatic Experiencing (Peter Levine): Focuses on completing truncated defensive responses — particularly the discharge of sympathetic activation trapped in immobility states. PVT provides the theoretical rationale for Levine's emphasis on titrated pendulation between activation and settling.
• The Safe and Sound Protocol (SSP): Developed directly by Porges, this is a five-hour auditory intervention using acoustically modified music filtered to emphasize the frequency band of human speech prosody (approximately 1,000-4,000 Hz). The theoretical mechanism is that stimulating the middle ear muscles via these frequencies activates the social engagement system and promotes ventral vagal regulation. The SSP has been tested in several clinical populations.

SSP Outcome Data

The evidence base for the SSP remains limited but growing:

• Porges et al. (2013, 2014) reported improvements in auditory processing, social behavior, and autonomic regulation in children with ASD following the SSP, with medium-to-large effect sizes on the Listening Project Protocol measures (d = 0.5-1.0 for specific social engagement metrics). However, these studies had small sample sizes (N = 11 to 80) and lacked blinded control conditions in some designs.
• A randomized controlled trial by Porges and colleagues (2014) in children with ASD showed improved auditory processing and spontaneous social behaviors, with RSA increases suggestive of improved vagal regulation. However, the study's sample size (N = 80) and short follow-up period limit generalizability.
• Preliminary data in adults with trauma histories suggest reductions in anxiety and improvements in social engagement following the SSP, but these are largely uncontrolled observations or small pilot studies. No large-scale RCTs with blinded assessors and active control conditions have been published as of 2024.

PVT in Attachment-Based Therapies

PVT provides a neurobiological rationale for the relational mechanisms in attachment-based therapies. The theory predicts that the therapist's regulated autonomic state — conveyed through prosody, facial expression, and calm presence — functions as a co-regulatory cue that activates the client's social engagement system. This maps onto the concept of interactive regulation in the developmental psychobiology literature (Schore, 2001) and the emphasis on therapeutic alliance in virtually all psychotherapy modalities. Research consistently shows that therapeutic alliance accounts for approximately 12-15% of outcome variance across treatment modalities (Norcross & Wampold, 2011), and PVT offers a biological mechanism for this finding.

HRV Biofeedback

HRV biofeedback — training individuals to increase RSA through resonance frequency breathing (typically around 5.5-6.5 breaths per minute) — is the most empirically supported intervention directly targeting vagal tone. Lehrer and Gevirtz (2014) provided a comprehensive review of mechanisms and applications. Key outcome data include:

• Depression: Caldwell and Steffen (2018) found that HRV biofeedback as an adjunct to psychotherapy produced significant reductions in depressive symptoms (large effect sizes, d > 0.8), though sample sizes were small.
• PTSD: Tan et al. (2011) reported significant PTSD symptom reduction with HRV biofeedback in a veteran sample, with clinically meaningful reductions on the PCL (PTSD Checklist).
• Anxiety: A meta-analysis by Goessl et al. (2017) found a large overall effect of HRV biofeedback on self-reported stress and anxiety (d = 0.81, 95% CI: 0.17-1.45), though heterogeneity was substantial.

The NNT for HRV biofeedback as a standalone intervention has not been well-established, and most evidence supports its use as an adjunctive rather than primary treatment modality.

One of PVT's most clinically useful contributions is the reconceptualization of low vagal tone as a transdiagnostic vulnerability factor rather than a disorder-specific biomarker. This aligns with the Research Domain Criteria (RDoC) framework's emphasis on dimensional constructs cutting across diagnostic categories.

Comorbidity Prevalence Estimates and Vagal Dysfunction

Conditions associated with reduced vagal tone show high rates of comorbidity, consistent with shared autonomic dysregulation:

• PTSD and MDD: Comorbidity rates range from 48-55% (Kessler et al., 1995, NCS data). Both conditions independently show reduced HF-HRV, and comorbid PTSD-MDD is associated with greater HRV reductions than either condition alone.
• PTSD and substance use disorders (SUD): Comorbidity rates of approximately 25-40% in clinical samples (NESARC data). Both conditions are associated with sympathetic hyperactivation and reduced vagal regulation.
• BPD and PTSD: Up to 25-58% of individuals with BPD meet criteria for comorbid PTSD (Pagura et al., 2010). Both conditions show autonomic dysregulation, and PVT-informed conceptualization suggests shared neuroceptive dysfunction — chronic threat detection in BPD may reflect developmental disruption of the ventral vagal system through early relational trauma.
• Functional somatic syndromes: Irritable bowel syndrome (IBS), fibromyalgia, and chronic fatigue syndrome show high psychiatric comorbidity (50-70% with anxiety or depression) and are consistently associated with reduced vagal tone. The vagus nerve directly innervates the gastrointestinal tract, and the gut-brain axis provides a direct pathway through which autonomic dysregulation impacts somatic function.

Developmental Considerations

Reduced vagal tone in infancy and childhood predicts later psychopathology. Porges and Furman (2011) reviewed evidence that baseline RSA and RSA reactivity in infancy predict behavioral regulation, emotional reactivity, and social competence in later childhood. Low RSA in infancy has been associated with increased risk for externalizing and internalizing problems, though effect sizes are typically small-to-medium and moderated by environmental factors including parental sensitivity and socioeconomic adversity.

The Adverse Childhood Experiences (ACE) literature converges with PVT in demonstrating that cumulative childhood adversity is associated with both reduced vagal tone and elevated risk for multiple psychiatric and medical conditions. Individuals with 4+ ACEs show a 4.7-fold increase in depression risk, a 12.2-fold increase in suicide attempt risk, and significantly reduced HRV compared to individuals with 0 ACEs — suggesting that chronic early threat exposure disrupts the development of ventral vagal regulatory capacity.

Vagal tone is not solely determined by environmental experience. Genetic and neurochemical factors contribute significantly to individual differences in autonomic regulation.

Genetic Factors

Twin studies estimate the heritability of resting HRV at approximately 40-65% (Kupper et al., 2005; Snieder et al., 2003), with the remaining variance attributable to shared and non-shared environmental factors. Specific genetic variants implicated include:

• CHRM2 (muscarinic acetylcholine receptor M2): The M2 receptor mediates vagal slowing of heart rate at the sinoatrial node. Polymorphisms in CHRM2 have been associated with individual differences in resting HRV and with risk for internalizing psychopathology, including depression and alcohol dependence.
• NOS1 (neuronal nitric oxide synthase): Nitric oxide is a co-transmitter in vagal neurotransmission, modulating the release of acetylcholine at cardiac vagal terminals. NOS1 variants have been linked to individual differences in cardiac vagal tone.
• COMT (catechol-O-methyltransferase): The Val158Met polymorphism, which influences prefrontal dopamine catabolism, has been indirectly linked to HRV through its effects on prefrontal cortical function and emotion regulation capacity.
• Oxytocin receptor gene (OXTR): Given oxytocin's role in social bonding and vagal regulation, OXTR polymorphisms (particularly rs53576) have been investigated in relation to both HRV and social engagement capacity, with some studies showing interactions between OXTR genotype and early environment in predicting vagal tone.

Neurochemical Systems

The primary neurotransmitter mediating vagal cardiac effects is acetylcholine (ACh), acting on muscarinic M2 receptors at the sinoatrial node to slow heart rate. However, multiple neurotransmitter systems modulate vagal output at the brainstem level:

• GABAergic inputs: The nucleus ambiguus receives substantial GABAergic inhibition. Benzodiazepines, which enhance GABA-A receptor function, can modulate vagal output — though the clinical significance for HRV is complex and dose-dependent.
• Glutamatergic inputs: Excitatory inputs to vagal motor neurons from the nucleus tractus solitarius (NTS), which processes afferent vagal sensory information from the baroreceptors and visceral organs, are glutamatergic and critically involved in the baroreflex arc.
• Serotonergic modulation: The raphe nuclei project to vagal motor nuclei, and serotonergic function modulates autonomic balance. SSRIs have variable effects on HRV — some studies show modest increases in HRV with SSRI treatment, while others show no significant change, likely reflecting the complexity of serotonergic modulation of autonomic circuits.
• Oxytocin: Centrally released oxytocin enhances vagal regulation and promotes social engagement behaviors. Intranasal oxytocin administration increases RSA in some studies (Kemp et al., 2012), providing a pharmacological bridge between the social engagement system and vagal tone.

Clinical outcomes in PVT-informed interventions are moderated by several factors that clinicians should consider in treatment planning.

Positive Prognostic Indicators

• Higher baseline RSA: Individuals with higher resting vagal tone show greater emotional flexibility and better treatment response across psychotherapy modalities. In depression treatment, higher baseline HRV predicted better response to both cognitive-behavioral therapy and antidepressant medication in several studies.
• RSA reactivity: The ability to appropriately suppress RSA under challenge (vagal withdrawal) and recover RSA after challenge (vagal recovery) predicts better emotional regulation and treatment response. This pattern reflects an intact "vagal brake" — the capacity to flexibly modulate autonomic state in response to environmental demands.
• Younger age: Vagal tone naturally declines with age at approximately 1-2% per year after age 30. Younger individuals generally show greater autonomic flexibility and greater capacity for vagal tone improvement with intervention.
• Secure attachment style: Attachment security is associated with higher baseline RSA and more adaptive RSA reactivity. Secure attachment likely reflects successful development of the social engagement system, providing a stronger foundation for PVT-informed interventions.
• Physical fitness: Aerobic fitness is robustly associated with higher vagal tone. Regular aerobic exercise produces increases in HRV with effect sizes of d = 0.3-0.5 in meta-analyses (Sandercock et al., 2005), providing an accessible adjunctive intervention.

Negative Prognostic Indicators

• Chronic, early-onset trauma: Developmental trauma disrupts the maturation of vagal regulatory circuits, and individuals with complex PTSD show more profound and treatment-resistant autonomic dysregulation than those with single-incident adult-onset PTSD.
• Dissociative presentations: Predominant dissociative responses — reflecting chronic dorsal vagal activation — are typically more treatment-resistant than hyperarousal-dominant presentations. The ICD-11 now recognizes complex PTSD as a distinct diagnosis, acknowledging the additional burden of disturbances in self-organization that correlate with more severe autonomic dysregulation.
• Medical comorbidity: Cardiovascular disease, diabetes, and other chronic conditions independently reduce HRV and may limit the degree of autonomic improvement achievable through psychological intervention.
• Polypharmacy: Multiple medications affecting autonomic function (anticholinergics, beta-blockers, benzodiazepines, tricyclic antidepressants) confound HRV assessment and may limit vagal tone improvement.

Despite PVT's clinical popularity, several of its core claims have been challenged by neuroscientists and comparative physiologists. A rigorous evidence-based approach requires acknowledging these criticisms.

Phylogenetic Claims

The most substantive criticism comes from comparative neuroanatomy. Paul Grossman (2023) and others have argued that:

• Myelinated vagal fibers are not unique to mammals. Myelinated vagal pathways have been documented in non-mammalian vertebrates, including fish, amphibians, and reptiles, undermining the claim that the VVC is a uniquely mammalian adaptation. Taylor et al. (1999, 2022) have demonstrated cardiac vagal control in multiple non-mammalian species.
• The dorsal-ventral distinction is oversimplified. The DMNX and NA both contain neurons that project to the heart and other thoracic/abdominal organs. The functional segregation between these nuclei is not as clean as PVT implies. Some DMNX neurons are myelinated, and some NA neurons project to non-cardiac targets.
• Reptilian immobility is not primarily vagally mediated. The claim that reptilian "freeze" is a dorsal vagal response is not consistently supported. Tonic immobility in many species involves complex interactions between multiple neural systems, not solely vagal activation.

The RSA-Specific Criticism

Grossman and Taylor (2007) have published detailed critiques arguing that RSA is not a pure index of cardiac vagal tone but is influenced by respiratory parameters (rate, depth, tidal volume), mechanical effects, and non-neural factors. They argue that uncorrected RSA values are unreliable as indices of vagal tone and that much of the PVT-derived literature fails to adequately control for respiratory variables. This is a methodologically important point: studies that do not measure or control for respiration when using HF-HRV as a vagal tone index may draw erroneous conclusions.

Neuroception: Conceptual vs. Empirical Status

Neuroception remains a primarily theoretical construct. While subcortical threat detection is well-established in affective neuroscience (e.g., LeDoux's fear conditioning work, Öhman's preattentive threat processing research), the specific claim that neuroception constitutes a distinct neural process — rather than a rebranding of established constructs like implicit threat appraisal or affective priming — has not been empirically differentiated. There is no validated measure of neuroception, no identified neuroceptive circuit distinct from known threat-detection circuits, and no established biomarker that indexes neuroception independently of general autonomic arousal.

Clinical Evidence vs. Clinical Adoption

There is a notable gap between PVT's widespread clinical adoption and the evidence supporting PVT-specific interventions. While HRV biofeedback has moderate empirical support, and PVT-informed psychotherapies overlap substantially with established trauma therapies (EMDR, CPT, PE), the incremental benefit of PVT-specific techniques — such as the SSP — over existing evidence-based treatments has not been demonstrated in head-to-head comparisons. No RCT has compared a PVT-specific protocol with an established trauma therapy such as prolonged exposure (PE) or cognitive processing therapy (CPT).

PVT is not the only framework linking autonomic function to emotion and psychopathology. Two related models deserve clinical attention:

Thayer's Neurovisceral Integration Model

Thayer and Lane (2000, 2009) proposed that HRV indexes the functional output of the central autonomic network (CAN), an interconnected set of brain structures including the mPFC, ACC, insula, amygdala, hypothalamus, PAG, and brainstem nuclei. In this model, high HRV reflects intact top-down prefrontal regulation of subcortical circuits, while low HRV reflects disinhibited subcortical activity — particularly amygdalar hyperreactivity. This model makes many of the same clinical predictions as PVT (reduced HRV in psychopathology, HRV as a biomarker of self-regulation) but without relying on the contested phylogenetic claims. It is more parsimonious and more firmly grounded in human neuroimaging evidence.

The Defense Cascade Model

Lang, Bradley, and colleagues, along with Kozlowska et al. (2015), have described a defense cascade progressing from freeze (attentive immobility with sympathetic activation) → flight → fight → tonic immobility (with parasympathetic dominance) → collapsed immobility. This model shares PVT's emphasis on a hierarchical progression of defensive responses but differs in several details — notably, the initial "freeze" in the defense cascade involves sympathetic activation (not parasympathetic), while PVT's dorsal vagal immobilization is a later-stage response. The defense cascade model is more directly grounded in experimental fear conditioning and predator defense research in animals.

Clinical Implications of Model Comparison

From a clinical standpoint, these models are more complementary than contradictory. The key convergent insight — that autonomic state profoundly shapes emotional, cognitive, and social functioning, and that restoring autonomic flexibility is therapeutically important — is well-supported regardless of which theoretical framework is preferred. Clinicians who use PVT as a clinical heuristic while acknowledging its phylogenetic oversimplifications are likely on sound ground; those who treat PVT's specific claims as established neuroscience risk overstating the evidence.

Several active areas of investigation are expanding, refining, or challenging PVT's claims:

• Vagal nerve stimulation (VNS): Invasive VNS is FDA-approved for treatment-resistant depression and epilepsy. Transcutaneous VNS (tVNS), typically applied to the auricular branch of the vagus nerve (tragus stimulation), is under investigation for depression, PTSD, anxiety, and inflammatory conditions. Preliminary RCTs show modest antidepressant effects of tVNS, with response rates of approximately 30-40% in treatment-resistant depression samples, though methodological quality varies. If tVNS proves effective, it would provide causal evidence for the therapeutic importance of vagal afferent signaling — supporting PVT's emphasis on vagal function, though through an afferent rather than efferent mechanism.
• Gut-brain vagal signaling: The vagus nerve is the primary neural conduit of the gut-brain axis. Emerging research links vagal afferent signaling from gut microbiota to mood, anxiety, and social behavior in animal models (Bravo et al., 2011). The vagal mediation of probiotic effects on anxiety and depression in humans is an active research frontier.
• HRV as a treatment outcome biomarker: Studies are examining whether changes in HRV during psychotherapy predict treatment response. If pre-to-post treatment HRV increases predict symptom remission, this would validate vagal tone as a treatment target — supporting PVT-informed interventions even if the phylogenetic details are incorrect.
• Wearable technology: Consumer-grade wearables (Apple Watch, WHOOP, Oura Ring) now provide continuous HRV monitoring. While measurement accuracy varies, these devices enable ecological momentary assessment of autonomic function and may facilitate real-time HRV biofeedback interventions outside clinical settings.
• Comparative neuroanatomy: Ongoing work by Taylor, Grossman, and others continues to test PVT's specific phylogenetic predictions in non-mammalian vertebrates. This work will ultimately determine whether PVT's evolutionary narrative is revised, retained, or abandoned.

Polyvagal Theory offers a clinically generative framework for understanding the autonomic dimensions of psychological distress, particularly in trauma, dissociation, and social engagement difficulties. However, responsible clinical application requires distinguishing between what PVT gets right, what it oversimplifies, and what remains unproven.

What Is Well-Supported

• Vagal tone (HRV) is a robust transdiagnostic biomarker of autonomic regulatory capacity, reduced across multiple psychiatric conditions.
• Autonomic state profoundly influences emotion, cognition, social behavior, and therapeutic engagement.
• Interventions targeting vagal tone (HRV biofeedback, aerobic exercise, breathing practices) show clinical benefit with moderate effect sizes.
• The therapeutic relationship involves co-regulation of autonomic states, and the clinician's prosody, facial affect, and calm presence are not merely "nonspecific factors" but active therapeutic mechanisms.
• Dissociative responses involve a shift toward parasympathetic dominance consistent with dorsal vagal activation.

What Is Oversimplified or Contested

• The strict phylogenetic hierarchy (unmyelinated vagus → sympathetic → myelinated vagus) does not accurately represent vertebrate autonomic evolution.
• The sharp dorsal/ventral vagal distinction oversimplifies brainstem anatomy.
• Neuroception, while clinically useful as a concept, has not been empirically distinguished from established constructs in affective neuroscience.
• RSA is a useful but imperfect index of vagal tone, requiring control for respiratory parameters.

Clinical Recommendations

• Use PVT as a clinical heuristic — a useful language for psychoeducation and clinical formulation — not as established neuroscience.
• Incorporate HRV monitoring (where feasible) as a biomarker of treatment progress.
• Prioritize evidence-based treatments (PE, CPT, EMDR for PTSD; CBT, IPT, antidepressants for depression) with PVT-informed adjuncts (HRV biofeedback, breathwork, vagal toning exercises) rather than relying on PVT-specific protocols as standalone interventions.
• When using PVT concepts in psychoeducation, frame them as models for understanding body-brain connection rather than as literal neuroanatomical descriptions.
• Assess and track HRV as an outcome biomarker alongside symptom measures, recognizing its limitations.